Cardiac Troponin I Concentration May Predict Mortality
THURSDAY, Aug. 10, 2023 (HealthDay News) -- Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart.
Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.
Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10 cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.
"These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Related Posts
Health Highlights: March 1, 2023
What exactly is hospice care? After the announcement that former President Jimmy...
Hospitals Are Rationing COVID-19 Pills, Infusions as Cases Rise
FRIDAY, Jan. 7, 2022 (HealthDay News) -- It is the ultimate irony: More COVID-19...
Health Highlights: March 1, 2022
Fewer breast cancers may be 'overdiagnosed' than thought. Detection of breast...